WO2008034117A3 - Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg-coa reductase and increase ldl receptor and sp1 expression in a mammal - Google Patents
Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg-coa reductase and increase ldl receptor and sp1 expression in a mammal Download PDFInfo
- Publication number
- WO2008034117A3 WO2008034117A3 PCT/US2007/078585 US2007078585W WO2008034117A3 WO 2008034117 A3 WO2008034117 A3 WO 2008034117A3 US 2007078585 W US2007078585 W US 2007078585W WO 2008034117 A3 WO2008034117 A3 WO 2008034117A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- expression
- hmg
- acetylation
- mammal
- inhibit
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title abstract 5
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 title abstract 4
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 title abstract 4
- 102000000853 LDL receptors Human genes 0.000 title abstract 4
- 108010001831 LDL receptors Proteins 0.000 title abstract 4
- 230000021736 acetylation Effects 0.000 title abstract 4
- 238000006640 acetylation reaction Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 101500000018 Glycine max 2S albumin small chain Proteins 0.000 abstract 4
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Controlled studies demonstrate that methods using soy related peptides inhibit H3 acetylation, reduce expression of HMG-CoA reductase and increase LDL receptor and Sp1 expression in mammals. The present disclosure is generally directed to using lunasin peptides and/or lunasin peptide derivatives to 1) inhibit H3 acetylation, 2) reduce expression of HMG-CoA reductase, 3) increase LDL receptor expression or 4) increase Sp1 expression in a mammal. In at least one exemplary embodiment of the present disclosure, an effective amount of lunasin peptides or lunasin peptide derivatives and one or more enzyme inhibitors is provided to a mammal to 1) inhibit H3 acetylation, 2) reduce expression of HMG-CoA reductase, 3) increase LDL receptor expression or 4) increase Sp1 expression in a mammal.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96652906P | 2006-09-16 | 2006-09-16 | |
| US11/532,528 | 2006-09-16 | ||
| US11/532,528 US7731995B2 (en) | 2006-09-16 | 2006-09-16 | Methods for using soy peptides to inhibit H3 acetylation, reduce expression of HMG CoA reductase, and increase LDL receptor and Sp1 expression in a mammal |
| US60/966,529 | 2006-09-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008034117A2 WO2008034117A2 (en) | 2008-03-20 |
| WO2008034117A3 true WO2008034117A3 (en) | 2008-06-05 |
Family
ID=39184637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2007/078585 WO2008034117A2 (en) | 2006-09-16 | 2007-09-15 | Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg-coa reductase and increase ldl receptor and sp1 expression in a mammal |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008034117A2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001072784A2 (en) * | 2000-03-24 | 2001-10-04 | Filgen Biosciences, Inc. | Peptides binding to non-acetylated h3 and h4 histones for cancer therapy |
-
2007
- 2007-09-15 WO PCT/US2007/078585 patent/WO2008034117A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001072784A2 (en) * | 2000-03-24 | 2001-10-04 | Filgen Biosciences, Inc. | Peptides binding to non-acetylated h3 and h4 histones for cancer therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008034117A2 (en) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006138238A3 (en) | Methods of protecting against apoptosis using lipopeptides | |
| WO2010060937A3 (en) | Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor | |
| WO2007056681A3 (en) | Methods for administering hypoglycemic agents | |
| WO2007008684A3 (en) | Ligands of melanocortin receptors | |
| WO2005117943A3 (en) | Biomarkers for monitoring inhibition of impdh pathway | |
| AU2007299726A8 (en) | Combination comprising an HMG-CoA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis | |
| WO2006078752A3 (en) | Inhibitors of dna methyltransferase | |
| WO2007081755A3 (en) | Indole-benzimidazole and indazole inhibitors of tyrosine phosphatases | |
| WO2007090384A3 (en) | Adhesives and adhesive methods | |
| AU2007306104A1 (en) | Hydrobenzamide derivatives as inhibitors of Hsp90 | |
| WO2009133374A3 (en) | Antisapstain compositions comprising a haloalkynyl compound, an azole and an unsaturated acid | |
| WO2008076427A3 (en) | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | |
| WO2007109037A3 (en) | Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids | |
| WO2006132959A3 (en) | Inhibition of thrombin generation | |
| WO2010066639A3 (en) | Skin lightening compositions with acetylcholinesterase inhibitors | |
| WO2007019526A3 (en) | Compositions and methods for controlling glucose and lipid uptake from foods | |
| MX2009013982A (en) | Compositions comprising tryptophan hydroxylase inhibitors. | |
| WO2010081143A3 (en) | Cymbal mounting assembly | |
| AU2007259257A8 (en) | Antitumoral dihydropyran-2-one compounds | |
| WO2007079916A3 (en) | Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes | |
| WO2007146445A3 (en) | Individualized pharmaceutical selection and packaging | |
| WO2007095250A3 (en) | Compositions and methods for inhibiting optic nerve damage | |
| WO2006069719A3 (en) | Lyophilization of virosomes | |
| WO2006117761A3 (en) | Magnesium salts of hmg-coa reductase inhibitors | |
| WO2006023866A3 (en) | Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07842568 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07842568 Country of ref document: EP Kind code of ref document: A2 |